Stock NSTM NOVELSTEM
Add to a list
To use this feature you must be a member
Log inSign up

NOVELSTEM Stock OTC Markets

Equities

NSTM

US4362331005

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 10:59:07 2021-10-05 am EDT 		5-day change 1st Jan Change
0.27 USD +7.57% Intraday chart for NOVELSTEM -3.50% +44.75%
Apr. 01 NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Financials (USD)

Sales 2022 0.01 Sales 2023 0.01 Capitalization 2.95M
Net income 2022 - Net income 2023 -4M EV / Sales 2022 757,203,750 x
Net Debt 2022 282K Net Debt 2023 3.52M EV / Sales 2023 539,198,333 x
P/E ratio 2022
-9.39 x
P/E ratio 2023
-0.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 33.68%
More Fundamentals * Assessed data

Chart NOVELSTEM

Dynamic Chart

Latest news about NOVELSTEM

NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Novelstem International Corp. Appoints Jan Loeb as President CI
NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
NovelStem International Corp. Elects Christine Jenkins as Chief Financial Officer CI
NovelStem International Corp. Elects Jan Loeb as Principal Executive Officer CI
NovelStem International Corp. Announces Management Changes CI
NovelStem International Corp and Newstem Ltd. Announce New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and Covid-19 Resistance CI
NovelStem International Corp.'s Equity Buyback announced on January 16, 2018, has expired. CI
Hollywood Media Corp. will Change its Ticker to NSTM from HOLL CI
Hollywood Media Corp. has Changed its Name to NovelStem International Corp CI
Hollywood Media Corp. Announces Board Changes CI
NewStem Ltd. announced that it expects to receive $4 million in funding from Hollywood Media Corp. CI
More news

Press releases NOVELSTEM

NOVELSTEM INTERNATIONAL CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) AQ
NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) AQ
NOVELSTEM INTERNATIONAL CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers (form 8-K) AQ
NovelStem Increases NewStem Ownership to 33% as NewStem Prepares for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares GL
More press releases

Managers and Directors - NOVELSTEM

Managers TitleAgeSince
Mitchell Rubenstein FOU
 Founder 70 93-01-21
Christine Jenkins DFI
 Director of Finance/CFO 61 22-09-28
Jan Loeb CHM
 Chairman 65 18-06-30
Members of the board TitleAgeSince
David Seltzer BRD
 Director/Board Member 64 -
Mitchell Rubenstein FOU
 Founder 70 93-01-21
Jan Loeb CHM
 Chairman 65 18-06-30
More insiders

Company Profile

NovelStem International Corp. is a development-stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.71% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.49% 96.73B
ARGENX SE Stock argenx SE
+0.12% 21.31B
BIONTECH SE Stock BioNTech SE
-16.61% 21.21B
GENMAB A/S Stock Genmab A/S
-5.94% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.14% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-27.40% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.44% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.29% 10.98B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NSTM Stock
  4. NSTM Stock